About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Resistant Bacteria in Children in France | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT06036628

Resistant Bacteria in Children in France

This study is observational, multicenter and prospective study for surveillance of the use of new antibiotics in pediatrics for treated pediatrics infections due to multi-resistant bacteria

Lead sponsor: Association Clinique Thérapeutique Infantile du val de Marne•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Association Clinique Thérapeutique Infantile du val de Marne

Collaborators

Pfizer

The main of this study is to evaluate the relevance of prescribing "new antibiotics" according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation As this is a surveillance study, the clinical and biological characteristics of the children included will be described.

Age

0 - 17 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Children under 18 years of age
•Hospitalized in France in a hospital center working with the ACTIV/GPIP network
•Treated with one or more of the following antibiotics:
•* Colimycin (Colistimethate sodium)
•* Cefiderocol
•* Aztreonam in combination
•* Ceftolozane-Tazobactam
•* Ceftazidime-avibactam
•* Meropenem/vaborbactam
•* Imipenem/Relebactam
•* Tigecycline
•* Daptomycin
•* Ceftaroline fosamil
•* Tedizolid phosphate
•* Fidaxomicin
•* Ceftobiprole
•* Dalbavancin
•In association with a documented infection performed by:
•Blood culture
•Normally sterile site
•* Cerebrospinal fluid
•* Pleural fluid
•* Pleura
•* Peritoneum
•* Joint fluid
•* Other
•Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000)
•Respiratory specimens if the bacteria was considered responsible for the infection
•Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),....
•* Related to colonization with multidrug-resistant bacteria without documentation.

Exclusion Criteria

•Refusal of participation by the patient or his/her parent
•Medical history of mucoviscidosis

Related studies

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

NCT04335383 · Pseudomonas Aeruginosa, Multi-antibiotic Resistance

RECRUITINGPhase 1/2

FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae

NCT05791396 · Enterobacteriaceae Infections, Multi-antibiotic Resistance

Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections

NCT02060513 · Infection, Skin and Subcutaneous Tissue Bacterial Infections, and more

Use of New Antibiotics in Sweden

NCT05048693 · Multi-antibiotic Resistance

Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

NCT06199141 · Respiratory Distress Syndrome, Adult, Multi-antibiotic Resistance

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 19, 2026Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment306

Start dateApr 2023

Last updatedMar 19, 2026

Condition

Infection Due to Resistant Bacteria Multi-antibiotic Resistance Antibiotic Prescription Risk Factors Healing+4 more

Locations shown

ACTIV

Créteil

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 19, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions